吉田 佳代

Medicine & Life Sciences

1. Brachytherapy 100%
2. Prostate 62%
3. Chemoradiotherapy 53%
4. Iodine-125 51%
5. Esophageal Neoplasms 49%
6. Esophagectomy 49%
7. Survival 46%
8. Seeds 43%
9. Prostate-Specific Antigen 37%
10. Prostatic Neoplasms 35%
11. Fluorouracil 34%
12. Cisplatin 32%
13. Radiotherapy 31%
14. Esophageal Squamous Cell Carcinoma 21%
15. Docetaxel 20%
16. Neoplasm Metastasis 18%
17. Survival Analysis 17%
18. Artifacts 17%
19. Palliative Care 17%
20. Metals 15%
21. Income 14%
22. Pneumonia 14%
23. Multivariate Analysis 14%
24. Tomography 12%
25. Recurrence 12%
26. Carcinoma 12%
27. Health Care Outcome Assessment 11%
28. Hemorrhage 11%
29. Disease-Free Survival 10%
30. Bone and Bones 10%
31. Safety 10%
32. Therapeutics 9%
33. Survival Rate 9%
34. Progression-Free Survival 8%
35. Planning Techniques 8%
36. Squamous Cell Neoplasms 7%
37. Salvage Therapy 7%
38. Neoplasm Grading 6%
39. Esophageal Stenosis 6%
40. Terminology 6%
41. Neoadjuvant Therapy 6%
42. Hormones 5%